Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. More Details
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Apellis Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APLS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: APLS's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: APLS exceeded the US Biotechs industry which returned 23.6% over the past year.
Return vs Market: APLS exceeded the US Market which returned 39.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Apellis Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?
2 months ago | Simply Wall StWhat Does The Future Hold For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)? These Analysts Have Been Cutting Their Estimates
3 months ago | Simply Wall StIf You Had Bought Apellis Pharmaceuticals (NASDAQ:APLS) Shares Three Years Ago You'd Have Earned 88% Returns
Is Apellis Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: APLS ($66.76) is trading below our estimate of fair value ($576.61)
Significantly Below Fair Value: APLS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: APLS is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: APLS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate APLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: APLS is overvalued based on its PB Ratio (104x) compared to the US Biotechs industry average (2.9x).
How is Apellis Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: APLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: APLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: APLS's revenue (60.8% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: APLS's revenue (60.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APLS's Return on Equity is forecast to be low in 3 years time (6.8%).
How has Apellis Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APLS is currently unprofitable.
Growing Profit Margin: APLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: APLS is unprofitable, and losses have increased over the past 5 years at a rate of 52.9% per year.
Accelerating Growth: Unable to compare APLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: APLS has a negative Return on Equity (-696.33%), as it is currently unprofitable.
How is Apellis Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: APLS's short term assets ($773.6M) exceed its short term liabilities ($83.7M).
Long Term Liabilities: APLS's short term assets ($773.6M) exceed its long term liabilities ($674.8M).
Debt to Equity History and Analysis
Debt Level: APLS's debt to equity ratio (747.5%) is considered high.
Reducing Debt: Insufficient data to determine if APLS's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APLS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: APLS has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 46.3% each year.
What is Apellis Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate APLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate APLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if APLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if APLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of APLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cedric Francois (49 yo)
Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...
CEO Compensation Analysis
Compensation vs Market: Cedric's total compensation ($USD9.28M) is above average for companies of similar size in the US market ($USD6.50M).
Compensation vs Earnings: Cedric's compensation has increased whilst the company is unprofitable.
Experienced Management: APLS's management team is considered experienced (3.3 years average tenure).
Experienced Board: APLS's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.5%.
Apellis Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Apellis Pharmaceuticals, Inc.
- Ticker: APLS
- Exchange: NasdaqGS
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.774b
- Shares outstanding: 86.49m
- Website: https://www.apellis.com
Number of Employees
- Apellis Pharmaceuticals, Inc.
- 100 Fifth Avenue
- United States
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammator...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/27 01:14|
|End of Day Share Price||2021/07/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.